A One-Year, Randomized, Double-Masked, Multicenter, Phase III, Two-Arm Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Chinese Patients With Visual Impairment Due to Diabetic Macular Edema
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment of Chinese patients with visual impairment due to Diabetic Macular Edema.
Diabetic Macular Edema
Aug 23, 2019
Oct 28, 2022
18 Years and older (Adult, Older Adult)
5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance
5 x every 4 weeks loading then every 8 weeks maintenance
Patients with type 1 or type 2 diabetes mellitus
Visual impairment due to Diabetic Macular Edema
Any active intraocular or periocular infection or active intraocular inflammation
Structural damage of the fovea
Neovascularization of the iris
Other protocol-defined inclusion/exclusion criteria may apply.